Biotron Ltd. | Balance Sheet

Fiscal year is July-June. All values AUD Thousands.
2014
2015
2016
2017
2018
Cash & Short Term Investments
1,779.30
4,538.40
3,418.50
1,987.40
1,543.00
Total Accounts Receivable
-
10.20
-
-
-
Other Current Assets
19.90
19.90
27.80
42.70
58.40
Total Current Assets
1,799.20
4,568.40
3,446.20
2,030.10
1,601.40
Net Property, Plant & Equipment
64.70
47.80
37.10
29.50
17.90
Total Assets
1,863.90
4,616.20
3,483.30
2,059.60
1,619.20
Accounts Payable
267.10
249.20
92.50
344.20
135.80
Other Current Liabilities
207.60
224.00
253.90
275.30
201.90
Total Current Liabilities
474.60
473.20
346.30
619.50
337.70
Total Liabilities
474.60
473.20
346.30
619.50
337.70
Common Equity (Total)
1,389.30
4,143.00
3,137.00
1,440.10
1,281.50
Total Shareholders' Equity
1,389.30
4,143.00
3,137.00
1,440.10
1,281.50
Total Equity
1,389.30
4,143.00
3,137.00
1,440.10
1,281.50
Liabilities & Shareholders' Equity
1,863.90
4,616.20
3,483.30
2,059.60
1,619.20

About Biotron

View Profile
Address
56 Delhi Road
North Ryde New South Wales (NSW) 2113
Australia
Employees -
Website http://www.biotron.com.au
Updated 07/08/2019
Biotron Ltd. is a clinical stage Australian biotechnology company. It engages in developing and commercializing a novel small molecule approach that has the potential to treat a number of serious viral diseases. The company's technology targets viroporin proteins, which are key to enabling the pathogenicity of a number of viruses including hepatitis C, HIV-1, Dengue, Zika, Influenza and Respiratory Syncytial Virus.